Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

By afschroeder • October 5, 2026

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds J, Medd P, Searle E, Sochacki A, Savoie ML, Green S, Kato K, Hernandez R, Metenou S, Ma B, Pandite L, Schreiber TH, Sallman DA. Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. Cancer. 2026 Oct 1;132(19):e70626. doi: 10.1002/cncr.70626. PMID: 42829896; PMCID: PMC13634416.

Tags: acute, CD40, CD47, Hematology/Oncology, immunotherapy, leukemia, Myelodysplastic syndromes, myeloid, Publications

Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma

Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla[...]

Psychosocial burden in cancer survivors

Ganz PA. Psychosocial burden in cancer survivors. Nat Rev Cancer. 2026 Oct 1. doi: 10.1038/s41568-026-00986-0. Epub ahead of print. PMID: 42823480.

Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model

Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang[...]